Italia markets closed

NuCana plc (N04A.F)

Frankfurt - Frankfurt Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
0,5700+0,0050 (+0,88%)
Alla chiusura: 09:32AM CEST

NuCana plc

3 Lochside Way
Edinburgh EH12 9DT
United Kingdom
44 13 1357 1111
https://www.nucana.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno31

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Hugh Stephen GriffithFounder, CEO & Exec. Director1,13MN/D1968
Mr. Donald MunozChief Financial OfficerN/DN/D1969
Prof. Christopher B. Wood FRCS, M.D., Ph.D.Chief Medical OfficerN/DN/D1946
Mr. David HarrisonHead of Translational MedicineN/DN/D1960
Ms. Theresa BruceSr. VP of Clinical OperationsN/DN/DN/D
Ms. Elisabeth OelmannSr. VP of Medical & Clinical Devel.N/DN/DN/D
Dr. Jeffrey D. Bloss F.A.C.O.G., M.D.Chief Medical OfficerN/DN/D1957
Martin QuinnCompany Sec.N/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di NuCana plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.